PASSCLAIM: diet-related cancer

Rafter, J., Govers, M., Martel, P., Pannemans, D., Pool-Zobel, B., Rechkemmer, G., Rowland, I., Tuijtelaars, S. and van Loo, J. (2004) PASSCLAIM: diet-related cancer. European Journal of Nutrition, 43 (S2). ii47-ii84. ISSN 1436-6215

Abstract/Summary

The strongest markers presently available are precancerous lesions (e. g. polyps or aberrant crypt foci) in humans and precancerous lesions and tumours in animal models. The only marker that presently can be used for a 'reduction of disease risk' claim (type B) for food components is 'polyp recurrence'. Type B claims cannot be made on the basis of results in animal models. All of the other biomarkers examined presently lack validation against the 'true endpoint', the tumour, and thus cannot be used for type B claims. 'Reduction of disease risk' claims in the area of 'diet-related cancer' should be based primarily on human intervention studies using relevant/acceptable endpoints. An important area for future research will be the validation of these surrogate endpoints.